



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 15th FEBRUARY 2017
AT 12.30pm**

**IN SEMINAR ROOM 7, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

| | |
|----------------------|--|
| Dr L Rogan (LR) | Head of Medicines Commissioning NHS EL CCG (Acting Chairperson) |
| Mrs C Woffindin (CW) | Medicines Information Manager, ELHT |
| Mr V Goodey (VG) | Assistant Director of Pharmacy, Clin Service ELHT |
| Dr S Jackson (SJ) | Clinical Commissioning Group MM Lead, GP EL |
| Mrs C Dugdale (CD) | Meds Management Pharmacist NHS BwD CCG |
| Mr A Gray (AG) | Clinical Pharmacist, ELHT |
| Mr J Vaughan (JV) | Commissioning Support Pharmacist NHS EL/BwD |
| Mrs L Holden (LH) | Pharmacist LCFT (representing Ms S Ramdour) |

In Attendance

| | |
|-------------|--|
| Ms L Prince | Medicines Management Technician EL CCG |
|-------------|--|

2017/013: APOLOGIES:

| | |
|--------------------|---|
| Dr D Gavan (DG) | Consultant Radiologist ELHT (Chairperson) |
| Mr N Fletcher (NF) | Director of Pharmacy ELHT |
| Dr K Burch (KB) | Consultant Microbiologist ELHT |
| Dr T McKenzie (TM) | GP, EL CCG |
| Dr S Davies (SD) | GP, EL CCG |

2017/014: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2017/015: MINUTES OF JANUARY MEETING:

Accepted as a correct record.

2017/016: MATTERS ARISING:

2016/155: Formulary Updates – Demeclocycline: LR to write to ask LMMG to review demeclocycline and tolvaptan.

2017/007: Formulary Updates – Sodium valproate – information from LCFT on referral of women of childbearing age on sodium valproate back to mental health services presented. Concerns were expressed that re-referral did not include all patients of childbearing age. It was agreed that LH would follow up with LCFT to consider if all previous mental health service patients of childbearing age on sodium valproate should be referred back to mental health services for review. CD to contact neurology again for their review plans for patients in their service.

2017/010: ELHE Medicine Sick Day Rules- Health professionals leaflet – the leaflet for health care professionals has been simplified to clarify the information and link with the ‘Think Kidneys’ website. It was agreed to amend the metformin statement to risk of renal impairment if eGFR < 30, then upload to website. A ‘Hot Topic’ will be produced and shared across the Health Economy.

2017/017: NEW PRODUCT REQUEST - ORKAMBI®

Orkambi® is requested by Dr Corbett, Consultant Paediatrician, for the treatment of cystic fibrosis for one patient. It is a licensed product, for a defined specific group of patients, but not yet considered by NICE or NHSE. The company will supply on a managed access program without charge until it is funded by the NHS.

It was agreed this patient who meets the criteria for treatment can receive Orkambi®. The prescribers to be reminded to consider future treatment pressures and exit strategies if NHS does not fund.

Resolved: Orkambi® agreed for one specific patient.

2017/018: NEW PRODUCT PROTOCOL - METHOXYFLURANE (PENTHROX®)

Methoxyflurane (penthrox®) for use in the emergency department was approved in principle in September 2016, but was awaiting a protocol to support its use. The protocol is now presented and is approved for use. Methoxyflurane (penthrox®) can now be used in the emergency department in accordance with the protocol.

Resolved: Methoxyflurane (penthrox®) is now approved for use in the emergency department in accordance with the protocol.

2017/019: LMMG CONSULTATIONS (for Mar LMMG)

Biosimilar Medicines Position Statement

Suggest that the initial sentence is long and complex and would benefit from rewording. It needs to be clear that the product with lowest acquisition cost should be used whether it is the parent product or a biosimilar.

Eflornithine Recommendation

In ELHE Eflornithine cream (Vaniqua) is currently assigned a Red light. Despite this there remains some prescribed in primary care. The draft LMMG recommendation is for a Black traffic light due to limited evidence of efficacy. It was suggested the recommendation should include all prescribing including transgender people. It was suggested to adopt the Fylde & Wyre advice sheet. Concern was expressed over the inclusion of co-cyprindol as a possible alternative due to clinical risks. ELMMB supported the black traffic light recommendation.

Relvar Ellipta® Recommendation

The fluticasone furoate/vilanterol 92/22 recommendation is to consider changing existing status to green based on a recent reduction in costs. The respiratory consultants support the recommendation. Despite a reduction in cost, clinicians were concerned over the quality and safety implications and associated risks with high potency ICS and difficulty identifying where this combination would fit in the existing pathway. ELMMB does not support the product as there is a drive to move away from using ICS in COPD due to additional risks eg. Pneumonia, there is a preference to use LABA/LAMA combination in accordance with GOLD standards, there is concern over increased potency of new salt compared with an already high potency ICS and associated risks and the lack of experience with vilanterol. ELMMB recommends remaining with the black traffic light. The ELHE, COPD guidelines to be updated and circulated to respiratory clinicians for comment.

Update of Rheumatoid Arthritis biologics pathway

The draft was sent out to specialists this week with responses due in a week. No comments from ELMMB. Any comments from specialists to be sent to LMMG

Resolved: CW to send responses to LMMG.

2017/020: LMMG RECOMMENDATIONS (from January)

Opicapone Recommendation - LMMG guideline accepted as written for ELHE.

Traffic light: Black

Degarelix Prescribing Information Sheet – the information sheet to support degarelix recommendation was accepted as written for ELHE.

Apomorphine Shared Care Guideline – accepted as written for ELHE.

ADHD medication Shared Care Guideline – now including guanfacine accepted as written for ELHE

Vitamin D Position Statement – The original guideline has been changed to this position statement. Concerns were expressed that the information in boxes 3 & 4 on page 2 is not accurate, the frequency of calcium monitoring is different on page 3 compared to page 2, new recommendations are for all population to supplement with Vitamin D in winter months, and the doses do not reflect local recommendations. Concerns were also expressed with the children's recommendations and the lack of information in pregnancy.

The comments on the position statement to be sent to LMMG. In ELHE need to review children's guideline and consider guidance in pregnancy. The products recommended in ELHE also require review.

Resolved: Recommendations accepted for ELHE as above to be uploaded to ELMMB website. Vitamin D comments to LMMG and local review work required.

2017/021: OPIOID TAPERING GUIDELINES – NON-CANCER PAIN

The LMMG opioid tapering guidelines for patients with non-cancer pain on doses above 120mg per day is incorporated as Appendix 5 of The Pharmacological Management of Adults with Non-Cancer Pain. These guidelines were accepted for use.

ELHE have developed a pathway for guidance on opioid tapering for patients taking 120-300mg and also for those taking above 300mg per day. This pathway is approved for use and to be uploaded to website together with the opioid tapering guidelines document (same as appendix 5 above).

It was also agreed to include a link to the neuropathic pain guidance on the non-cancer pain management document and vice versa.

Resolved: Opioid Tapering Guidelines and pathways approved.

2017/022: FORMULARY UPDATES

Perampanil – changed from red to amber traffic light in line with LMMG recommendation. **Traffic Light: Amber**

Pregabalin - Alzain[®] – to be added as an option. **Traffic Light: Green**

Sodium Chloride oral solution 5mMol/mL – add to formulary with Amber traffic light. **Traffic Light: Amber**

Omeprazole 10mg dispersible tablets – add to formulary for use in paediatrics. **Traffic Light: Amber**

Resolved: Formulary to be updated as above.

2017/023: ELHT ANTIMICROBIAL FORMULARY – MAXFAX GUIDELINES

New section for maxfax for secondary care antimicrobial guidelines, agreed with directorate & microbiology. Approved for use.

Resolved: ELMMB approved.

2017/024: ELHT ANTIMICROBIAL FORMULARY – RADIOLOGY INTERVENTIONS UPDATED

Updated radiology section for secondary care antimicrobial guidelines, agreed with directorate & microbiology. Approved for use.

Resolved: ELMMB approved.

2017/025: ELHT ANTIMICROBIAL FORMULARY – VARICEAL BLEEDING & SPONTANEOUS BACTERIAL PERITONITIS UPDATED

Updated guidance for variceal bleeding and spontaneous bacterial peritonitis indications in secondary care antimicrobial guidelines to reduce the use of Piperacillin/Tazobactam in line with CQUIN, agreed with directorate & microbiology. Approved for use.

Resolved: ELMMB approved.

2017/026: ELHT ANTIMICROBIAL FORMULARY – ORAL CANDIDIASIS TREATMENT UPDATED

Updated guidance for treatment of oral candidiasis for secondary care antimicrobial guidelines, agreed with microbiology. Approved for use. Check with microbiology if primary guidance should be updated.

Resolved: ELMMB approved.

2017/027: PENNINE LANCS CCG's RESEARCH POLICY

The Pennine Lancs Research and Development Policy outlines a process for reviewing research including trials involving medicines or with medicines implications. These would be assessed through the ELMMB and recommendations would go to the CCGs Quality Committee. It was suggested that all existing trials and research across primary and secondary care is collated and summarised. This will enable the group to have oversight of the research as well as having the potential to inform the pathway development and/or redesign. VG/LR to pull together a summary of existing research across secondary and primary care respectively.

Resolved: ELMMB acknowledged.

2017/028: EL MEDICAL SERVICES – OUT OF HOURS FORMULARY UPDATE

The out of hours formulary for EL Medical services has been updated. It was noted that prednisolone soluble tablets need to be removed and Adrenaline mini jet brand needs to be changed.

Resolved: ELMMB supported the policy.

2017/029: ELHE NICOTINE REPLACEMENT THERAPY POSITION STATEMENT

The position statement is to direct patients to an appropriate service for NRT. The BwD details to be added as they use a different service to EL.

Resolved: ELMMB supported the position statement.

2017/030: EL CCG GLUTEN FREE POLICY STATEMENT AND RESOURCES

Gluten Free position statement is now supported across EL and BwD CCGs. BwD CCG went live on 1st January 2017 and EL is scheduled for 1st April 2017. Resources to support practices and patients were shared with members. These will be uploaded to the ELMMB website.

Resolved: ELMMB acknowledged.

2017/031: NICE RECOMMENDATIONS (from Jan)

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TAG427) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.

Traffic Light: RED

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TAG 428) is recommended as an option by NICE. Approved in line with NICE. . NHS England commissioned.

Traffic Light: RED

Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TAG 429) is recommended as an option by NICE. Approved in line with NICE. . NHS England commissioned.

Traffic Light: RED

Sofosbuvir–velpatasvir for treating chronic hepatitis C (TAG 430) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.

Traffic Light: RED

Mepolizumab for treating severe refractory eosinophilic asthma (TAG 431) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.

Traffic Light: RED

2017/032: EARLY ACCESS TO MEDICINES SCIENTIFIC OPINION (from Jan)

Atezolizumab for treatment of locally advanced or metastatic urothelial carcinoma after disease progression following one prior platinum-containing chemotherapy regimen regardless of its setting (neoadjuvant, adjuvant, or metastatic) is included on the Early Access to Medicines Scheme.

STANDING ITEMS

2017/033: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – January 2017

Minutes acknowledged

2017/034: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – November 2016

Minutes acknowledged

ANY OTHER BUSINESS:

The primary care UTI chart has been updated with the formulary products.

DATE OF NEXT MEETING – Next meeting is **Wednesday 15th March 2017 12.30pm**, Seminar Room 6, Learning and Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 15TH FEBRUARY 2017

| MINUTE NUMBER | DESCRIPTION | ACTION | DATE |
|----------------------|---|----------------|----------------------------|
| 2016/155 | Formulary Updates – Demeclocycline – request LMMG to review demeclocycline and tolvaptan | LR | Feb 17 |
| 2017/007 | Formulary Updates – Sodium valproate – ask LCFT to consider all patients to be referred back. Discuss with neurology | LH CD | Mar 17 Mar 17 |
| 2017/020 | LMMG Recommendations (from Jan)- Vitamin D Position Statement – send comments to LMMG Review ELHE paediatric guidance Consider pregnancy guidance Review local products | CW LR LR | Mar 17 Apr 17 Apr 17 |
| 2017/026 | ELHT Antimicrobial Formulary – oral candidiasis updated – check if primary care guidance should be updated | LR | Apr 17 |